Clinical evaluation of Cytokine-induced killer cells combination with chemotherapy in patients with advanced pancreatic cancer
10.3969/j.issn.1006-5725.2015.13.025
- VernacularTitle:细胞因子诱导的杀伤细胞治疗晚期胰腺癌临床效果分析
- Author:
Dong SHEN
;
Tao LIU
;
Qingfeng LIN
;
Xiangdong LU
;
Qiong WANG
;
Feng LIN
;
Weidong MAO
- Publication Type:Journal Article
- Keywords:
Cytokine-induced killer cells;
Gemcitabine;
Pancreatic cancer;
Efficacy
- From:
The Journal of Practical Medicine
2015;(13):2148-2151
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of the cytokine-induced killer cells (CIK) treated in patients with advanced pancreatic cancer. Methods 74 cases (hospitalized from January 2012 to December 2013) with advanced pancreatic cancer (Ⅲ ~ Ⅳ stage) were selected. The patients were randomly divided into two groups: CIK cells treated group (38 patients) and chemotherapy group (36 cases). Patients in CIK cells group received CIK cell infusion therapy , and patients in chemotherapy group received only gemcitabine. The efficacy and safety of all patients were observed. Results The efficacy rate of CIK cells group was 29.0%, with no statistical significance compared to chemotherapy alone group (16.7%). Disease control rate was 63.2%, with statistical significance compared to the chemotherapy group (38.9%). The PFS was 3 months (95%CI:2.5 ~ 3.5), OS 6.8 months (95%CI:6.1 ~ 7.5). 6-month survival rate 41.7%, with statistically significance compared to chemotherapy group. Conclusion CIK cells treated in patients with advanced pancreatic cancer is feasible and safe , and can improve disease control rate , improve immunity and produce clinical benefit in patients.
